论文部分内容阅读
为探索食管癌超分割放疗适宜的剂量，１９８７年３～９月我们对８０例中段食管鳞癌患者随机分为３组进行对照研究：Ａ组总量为６０～７０Ｇｙ／６～７周，每天１次２Ｇｙ，每周５次；Ｂ组总量为５１Ｇｙ／２３天，每天２次，每；１．５Ｇｙ；Ｃ组总量为５０Ｇｙ／２３天，每天３次，每次１Ｇｙ。所有病人随诊超过５年，５年生存率Ａ、Ｂ、ＣＭ组分别为１１．１％、３７％和２３．１％。Ｂ组与Ａ组比较Ｐ＜０．０５。结果表明，总量为５１Ｇｙ的每天２次超分割放疗，具有疗程短、经济负担轻、生存率高等优点，治疗食管癌是可行的。
In order to explore the appropriate dose for hyperfractionation of esophageal cancer, from March to September 1987, we randomly divided 80 patients with esophageal squamous carcinoma of the middle segment into 3 groups: a total of 60-70 Gy for 6 to 7 weeks in A group. 1 2Gy, 5 times a week; B group total 51Gy/23 days, 2 times a day, each; 1.5Gy; C group total 50Gy/23 days, 3 times a day, each time 1Gy. All patients were followed up for more than 5 years. The 5-year survival rates in the A, B, and CM groups were 11.1%, 37%, and 23.1%, respectively. The P group was compared with group A P<0.05. The results showed that the total amount of 51Gy twice daily hyperfractionated radiation therapy has the advantages of short course of treatment, light economic burden and high survival rate. It is feasible to treat esophageal cancer.